Residency · Residency · Cardiology

Aortic Stenosis: Evaluation and Intervention

Etiology and Natural History

Etiologies by Age

Calcific or degenerative aortic stenosis is the most common etiology in patients over 65 years of age, resulting from progressive fibrocalcific remodeling of a trileaflet aortic valve. Risk factors mirror those of atherosclerosis and include advanced age, hypertension, hyperlipidemia, diabetes mellitus, smoking, and chronic kidney disease. Bicuspid aortic valve represents the most common congenital heart defect, with a prevalence of 1 to 2%, and is characterized by accelerated calcification that leads to clinically significant stenosis 10 to 20 years earlier than in trileaflet valves. Bicuspid aortic valve is also associated with aortopathy, including ascending aortic dilation that carries risk of dissection and rupture. Rheumatic aortic stenosis, caused by commissural fusion with thickened and retracted leaflets, is almost always accompanied by mitral valve involvement and continues to decline in prevalence in developed countries.

Natural History

Aortic stenosis is characterized by a prolonged asymptomatic phase during which gradual hemodynamic progression occurs. On average, peak aortic velocity increases approximately 0.3 m/s per year, mean gradient rises approximately 7 mmHg per year, and aortic valve area decreases approximately 0.1 cm^2 per year, though these rates are highly variable among individuals. Faster progression is associated with heavy calcification, bicuspid aortic valve, chronic kidney disease, and older age. The onset of symptoms marks a critical transition in the disease trajectory, with the classic symptom triad of angina, syncope, and heart failure. Once symptoms develop, prognosis without intervention is poor: angina is associated with a median survival of approximately 5 years, syncope with approximately 3 years, and heart failure with approximately 2 years. Sudden death in the asymptomatic severe aortic stenosis population is rare, occurring at a rate below 1% per year.

Echocardiographic Assessment

Severity Grading

Aortic stenosis severity is graded by multiple hemodynamic parameters. Mild disease corresponds to a peak velocity below 3.0 m/s, mean gradient below 20 mmHg, and aortic valve area above 1.5 cm^2. Moderate disease falls within a peak velocity of 3.0 to 3.9 m/s, mean gradient of 20 to 39 mmHg, and aortic valve area of 1.0 to 1.5 cm^2. Severe disease is defined by a peak velocity of 4.0 m/s or greater, mean gradient of 40 mmHg or greater, and aortic valve area below 1.0 cm^2, or below 0.6 cm^2/m^2 when indexed to body surface area. Very severe or critical aortic stenosis is characterized by a peak velocity of 5.0 m/s or greater and mean gradient of 60 mmHg or greater.

Continuity Equation for AVA

Aortic valve area is calculated using the continuity equation: AVA equals the product of LVOT area and LVOT VTI divided by AV VTI. The LVOT area is derived from the formula pi multiplied by the LVOT diameter divided by two, squared, with the diameter measured in the parasternal long-axis view at mid-systole using inner edge to inner edge technique. The LVOT VTI is obtained with pulsed-wave Doppler in the apical 5-chamber view with the sample volume placed in the LVOT just proximal to the aortic valve. The AV VTI is obtained with continuous-wave Doppler through the aortic valve from the apical window, with the critical instruction to use the highest velocity obtained from multiple acoustic windows including apical, right parasternal, and suprasternal. A critical pitfall is LVOT diameter measurement error: because the diameter is squared in the calculation, a 1 mm error causes approximately 10% error in the calculated valve area, necessitating careful measurement and averaging of multiple determinations.

Discordant Grading

Low-flow, low-gradient severe aortic stenosis with reduced ejection fraction represents the classic low-flow low-gradient pattern, characterized by an ejection fraction below 50%, aortic valve area below 1.0 cm^2, and mean gradient below 40 mmHg. Dobutamine stress echocardiography is the key test to differentiate true-severe from pseudo-severe disease. In true-severe stenosis, the aortic valve area remains below 1.0 cm^2 with increased flow, demonstrated by stroke volume augmentation of 20% or greater, and the projected valve area at a flow rate of 250 mL/s remains below 1.0 cm^2. In pseudo-severe stenosis, the valve area increases to above 1.0 cm^2 with augmented flow because the leaflets have flow reserve. Lack of flow reserve, defined as less than 20% stroke volume augmentation, portends high operative risk but does not preclude intervention if disease is anatomically severe.

Paradoxical low-flow, low-gradient aortic stenosis with preserved ejection fraction is characterized by an ejection fraction of 50% or greater, indexed stroke volume below 35 mL/m^2, aortic valve area below 1.0 cm^2, and mean gradient below 40 mmHg. This pattern is common in elderly, hypertensive patients with small left ventricular cavities. Confirmation of severity relies on aortic valve calcium score on CT, with thresholds of above 1200 Agatston units for women and above 2000 for men indicating severe disease, along with indexed valve area below 0.6 cm^2/m^2, exercise testing for symptom provocation, and energy loss index assessment.

Aortic Valve Calcium Scoring (CT)

The aortic valve calcium score provides a flow-independent, purely anatomical measure of disease burden. Sex-specific thresholds indicate that severe aortic stenosis is likely when the calcium score exceeds 2000 Agatston units in men or 1200 in women, with very severe disease suggested by scores exceeding 3000 in men and 1600 in women. This measurement is particularly valuable in discordant grading scenarios involving low-flow, low-gradient disease to confirm anatomical severity.

<image> A comprehensive diagram showing four hemodynamic patterns of aortic stenosis. Four panels arranged in a 2x2 grid. Panel 1 (top left): "High-Gradient Severe AS" - CW Doppler showing peak velocity 4.5 m/s, mean gradient 50 mmHg, AVA 0.8 cm^2; with schematic showing normal EF and adequate stroke volume. Panel 2 (top right): "Classic Low-Flow Low-Gradient" - CW Doppler showing peak velocity 3.2 m/s, mean gradient 25 mmHg, AVA 0.7 cm^2; schematic showing dilated LV with reduced EF (30%), reduced SV. Arrow to DSE result showing AVA still < 1.0 = true severe. Panel 3 (bottom left): "Paradoxical Low-Flow Low-Gradient" - CW Doppler showing peak velocity 3.5 m/s, mean gradient 30 mmHg, AVA 0.9 cm^2; schematic showing small hypertrophied LV with normal EF (60%) but indexed SV < 35 mL/m^2. Arrow to CT calcium score showing >2000 AU confirming severity. Panel 4 (bottom right): "Normal Flow, Low-Gradient (Moderate AS)" - CW Doppler peak velocity 3.0 m/s, mean gradient 18 mmHg, AVA 1.2 cm^2; schematic showing normal LV. Each panel with clear Doppler envelope shape, labeled measurements, and color-coded border (red = severe/intervention needed, yellow = further workup, green = moderate/observe). </image>

Indications for Intervention

Symptomatic Severe AS (Class I)

Intervention is indicated as a Class I recommendation for severe aortic stenosis by any criterion when symptoms attributable to the valve disease are present, including exertional dyspnea, angina, syncope, or heart failure. Both surgical aortic valve replacement and transcatheter aortic valve replacement are options, with the choice determined by the patient's risk profile and anatomic considerations.

Asymptomatic Severe AS (Evolving Indications)

The indications for intervention in asymptomatic severe aortic stenosis continue to evolve. Class I indications include asymptomatic severe AS with left ventricular ejection fraction below 50%, which likely represents early ventricular decompensation, and asymptomatic severe AS in patients undergoing other cardiac surgery such as CABG, aortic surgery, or other valve surgery. Class IIa indications encompass asymptomatic very severe AS with peak velocity of 5.0 m/s or greater or mean gradient of 60 mmHg or greater in patients with low surgical risk; asymptomatic severe AS with rapid hemodynamic progression, defined as velocity increase of 0.3 m/s per year or greater; asymptomatic severe AS with exercise-induced symptoms or blood pressure decline on exercise testing; and asymptomatic severe AS with elevated BNP exceeding three times the upper limit of normal, very high aortic valve calcium score, or reduced global longitudinal strain.

Exercise Testing in Asymptomatic Severe AS

Exercise testing is safe when performed under supervised conditions with experienced staff and is contraindicated only in patients with symptomatic severe aortic stenosis. A positive test is defined by exercise-limiting symptoms including dyspnea, angina, or lightheadedness, a fall in systolic blood pressure below baseline, or complex ventricular arrhythmias. A markedly abnormal exercise test in the setting of asymptomatic severe AS should prompt consideration of intervention.

Surgical Aortic Valve Replacement (SAVR)

Prosthesis Selection

Mechanical prostheses, including bileaflet tilting disc designs such as the St. Jude and On-X valves, require lifelong anticoagulation with a target INR of 2.5 to 3.5 for the aortic position and are generally favored in patients under 50 years of age per the 2020 ACC/AHA guidelines. Bioprosthetic valves, constructed from bovine pericardium or porcine tissue, undergo structural valve degeneration over approximately 10 to 15 years in the aortic position, with faster degeneration in younger patients, but do not require long-term anticoagulation beyond aspirin and 3 to 6 months of warfarin or DOAC. The decision between mechanical and bioprosthetic valves involves shared decision-making that considers age, anticoagulation tolerance, desire for future pregnancy, lifestyle, and likelihood of reintervention.

Operative Risk Assessment

The STS-PROM score predicts 30-day mortality and morbidity, incorporating risk factors including age, renal function, frailty, prior cardiac surgery, and emergent status. Low risk is defined as an STS score below 4% with a 30-day mortality of 1 to 2%. Intermediate risk corresponds to an STS score of 4 to 8%, while high risk exceeds 8%. Prohibitive risk implies predicted mortality or irreversible morbidity exceeding 50% at one year, or the presence of anatomic contraindications to surgery.

Transcatheter Aortic Valve Replacement (TAVR)

Landmark Trials

The evolution of TAVR evidence has been defined by a series of landmark trials. PARTNER 1A in 2010 demonstrated TAVR superiority over medical therapy in inoperable patients with a number needed to treat of 5 at one year for mortality. PARTNER 1B showed TAVR non-inferiority to SAVR in high-risk patients. PARTNER 2A in 2016 established non-inferiority in intermediate-risk patients. PARTNER 3 in 2019 demonstrated TAVR superiority over SAVR for the composite of death, stroke, and rehospitalization at one year using the balloon-expandable SAPIEN 3 valve in low-risk patients. The Evolut Low Risk trial in 2019 demonstrated non-inferiority of the self-expanding CoreValve Evolut system to SAVR in the low-risk population. Long-term data at 5 to 10 years show comparable outcomes between SAVR and TAVR at 5 years in intermediate-risk patients, with ongoing concerns about structural valve degeneration with TAVR in younger patients given limited data beyond 10 years.

Current Indications by Risk

For prohibitive and high surgical risk patients, TAVR is the preferred approach as a Class I recommendation. In intermediate-risk patients over 65, TAVR or SAVR are both acceptable options through shared decision-making as a Class I recommendation. In low-risk patients aged 65 or older, TAVR is a Class IIa option alongside SAVR with shared decision-making. For young patients under 65, SAVR is generally preferred given the uncertain long-term durability of TAVR valves, with mechanical SAVR providing the additional advantage of avoiding reintervention. Bicuspid aortic valve patients are increasingly undergoing TAVR with newer-generation devices, though higher rates of paravalvular leak and non-circular expansion were observed with older devices.

Pre-Procedural CT Assessment

CT imaging is the gold standard for TAVR planning. Annulus sizing requires multiplanar reconstruction to account for the elliptical annulus geometry, with measurements including perimeter-derived diameter, area-derived diameter, and maximum and minimum diameters. Coronary height assessment ensures adequate clearance, with left main height above 12 mm and right coronary height above 10 mm from the annulus considered safe, with lower heights increasing the risk of coronary obstruction. Sinus of Valsalva dimensions are evaluated for adequacy of leaflet clearance. Access route assessment determines iliofemoral artery diameter, requiring a minimum of 5.0 to 6.5 mm depending on the device, along with assessment of calcification and tortuosity. Alternative access routes include subclavian, direct aortic, transcarotid, and transcaval approaches. Severe LVOT calcification increases the risk of annular rupture, particularly with aggressive sizing or balloon post-dilation.

Complications

Paravalvular leak is the most common issue, with mild leak occurring in 30 to 40% and moderate-to-severe leak in 5 to 10%, the latter being associated with increased mortality and amenable to treatment with post-dilation or plug closure. Conduction disturbances are significant, with new left bundle branch block occurring in 25 to 35% with self-expanding valves and 10 to 15% with balloon-expandable valves, and complete heart block requiring permanent pacemaker in 10 to 20% with CoreValve and 5 to 10% with SAPIEN devices. Pre-existing right bundle branch block is the highest risk factor for permanent pacemaker requirement. Stroke occurs in 1 to 3% at 30 days, with cerebral embolic protection devices potentially reducing subclinical events. Vascular complications occur in 5 to 10% but have improved with smaller delivery systems. Coronary obstruction is rare at below 1% but catastrophic when it occurs, with risk factors including low coronary height, small sinuses, female sex, and valve-in-valve procedures. Subclinical leaflet thrombosis, detected as hypoattenuating leaflet thickening on CT in 10 to 15% of cases, has uncertain clinical significance but may respond to anticoagulation.

<image> A detailed anatomical illustration showing the TAVR procedure with a balloon-expandable valve (SAPIEN 3). The image should depict a cross-section of the aortic root in long axis view showing: (1) the delivery catheter crossing the native calcified aortic valve from a retrograde transfemoral approach, (2) the prosthetic valve (metallic frame with bioprosthetic leaflets) deployed at the level of the native annulus, (3) the relationship to the left main coronary ostium above the deployed valve, (4) the conduction system (AV node in the right trigone area, His bundle traversing the membranous septum) with an annotation showing proximity to the valve frame (explaining conduction disturbance risk), (5) the native valve leaflets compressed between the prosthesis and aortic wall. Label: native calcified leaflets, prosthetic valve frame, bioprosthetic leaflets, coronary ostia (left main and RCA), membranous septum with His bundle, LVOT, ascending aorta. Use anatomic coloring with metallic gray for the valve frame. </image>

Post-Procedural Management

Antithrombotic Therapy After TAVR

Current guideline recommendations based on the POPular-TAVI trial support aspirin monotherapy at 81 mg after TAVR, which proved superior to dual antiplatelet therapy with fewer bleeding events. For patients with concomitant atrial fibrillation, a DOAC alone without antiplatelet therapy is recommended per the ENVISAGE-TAVI AF and ATLANTIS subgroup data, with warfarin as an alternative. For patients with recent PCI within three to six months, DOAC or aspirin plus a P2Y12 inhibitor is guided by the balance of bleeding and ischemic risk.

Surveillance

Echocardiographic surveillance follows a structured protocol with baseline imaging before discharge, at 30 days, at one year, and then annually. Monitoring focuses on prosthetic valve stenosis with elevated gradients, new or worsening paravalvular regurgitation, and left ventricular recovery. Expected hemodynamics include a mean gradient typically of 10 to 15 mmHg for 23 to 26 mm valves, with gradients exceeding 20 mmHg raising concern for valve degeneration, thrombosis, or patient-prosthesis mismatch.

Key Clinical Pearls

• Always use multiple acoustic windows to obtain the highest AV velocity -- right parasternal window with a Pedoff probe frequently yields the highest gradient and is commonly omitted
• In low-flow, low-gradient AS with reduced EF, dobutamine stress echo differentiates true-severe (will benefit from intervention) from pseudo-severe (may not benefit); lack of contractile reserve portends high operative risk but does not preclude intervention if anatomically severe
• Aortic valve calcium score on CT is the most reliable severity marker in discordant grading scenarios (low-gradient with preserved EF) -- it is flow-independent and directly quantifies disease burden
• Pre-existing RBBB is the strongest predictor of permanent pacemaker after TAVR -- counsel these patients about ~40-50% PPM rate; consider pre-procedural electrophysiology evaluation
• Paradoxical low-flow, low-gradient AS is commonly missed -- always calculate indexed stroke volume in patients with small hypertrophied LV and apparently moderate AS; these patients benefit from intervention
• BAV patients undergoing TAVR or SAVR must have concomitant aortopathy assessment -- ascending aorta > 4.5 cm warrants surgical intervention at the time of AVR

References

• Otto CM, et al. 2020 ACC/AHA Guideline for the Management of Patients with Valvular Heart Disease. Circulation. 2021;143:e72-e227.
• Mack MJ, et al. Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients (PARTNER 3). NEJM. 2019;380:1695-1705.
• Popma JJ, et al. Transcatheter Aortic-Valve Replacement with a Self-Expanding Valve in Low-Risk Patients (Evolut Low Risk). NEJM. 2019;380:1706-1715.
• Baumgartner H, et al. 2017 ESC/EACTS Guidelines for the Management of Valvular Heart Disease. Eur Heart J. 2017;38:2739-2791.
• Clavel MA, et al. Validation of Conventional and Simplified Methods to Calculate Projected Valve Area at Normal Flow Rate in Patients with Low-Flow, Low-Gradient Aortic Stenosis. JACC. 2010;55:2783-2790.

Read this lecture as Markdown